Core Insights - The 2025 TBI Top Brand Innovation Awards recognized Huaxia Eye Hospital for its comprehensive brand advantages, winning the "Annual Brand Award" [1][4] Group 1: Award Significance - The TBI Top Brand Innovation Awards, now in its sixth year, is a prestigious honor in China, focusing on brand growth paths in the digital age and recognizing brands with innovation, foresight, and practical value [4] - This year's awards attracted participation from 578 companies, including major brands like Nestlé, Volkswagen, and Coca-Cola, showcasing 1,744 innovative works [4] Group 2: Brand Development - Huaxia Eye Hospital has successfully transitioned from "brand awareness" to "brand value," emphasizing a patient-centered approach and a commitment to enhancing medical, social, and ecological value [7] - The hospital integrates medical education and research, being one of the few large eye care chains in China with "double three A" certifications and three international ophthalmology academicians [8] Group 3: Social Responsibility - Huaxia Eye Hospital has a long-standing commitment to social value, conducting free eye care initiatives in countries along the Belt and Road, and has assisted in screening 20 million people for myopia prevention [10] - The hospital has launched various public health initiatives, including an AI self-test tool for dry eye, reaching 360 million patients [10] Group 4: Ecological Value - The hospital is expanding its brand through cross-industry collaborations, such as a joint public welfare initiative with Nova Coffee, promoting a "consumption equals public welfare" model [12] - Huaxia Eye Hospital is building a sustainable brand ecosystem by integrating medical, social, and ecological values, aiming for continuous evolution and collaboration [12][14]

Core Viewpoint - The "domestically produced all-laser refractive surgery machine" developed by Professor Zhang Mingchang's team has been recognized as one of the "Top Ten Original Advances in Ophthalmology in China for 2025," marking a significant breakthrough in the field of high-end laser treatment equipment for myopia refractive surgery in China [1][7]. Group 1: Research and Development Achievements - Professor Zhang Mingchang's team has been dedicated to the innovation and research of ocular surface diseases and refractive treatment technologies [3][9]. - The team previously developed the "tear lipid content detection test strip," which was included in the "Top Ten Advances in Chinese Ophthalmology" in 2021 [3][9]. Group 2: Technological Breakthroughs - The newly developed device achieves significant technological breakthroughs in laser energy control, beam positioning accuracy, and surgical process stability, specifically designed for myopia refractive surgery [5][11]. - The core optical system and intelligent control platform of the device are entirely developed domestically, breaking the long-standing reliance on imported equipment [5][11]. Group 3: Market Impact and Future Prospects - The device is expected to provide higher quality and more accessible high-end refractive surgery options for myopia patients, potentially lowering surgical costs and benefiting many individuals seeking vision correction [5][11]. - The development and transformation of this achievement exemplify successful collaboration between medical engineering and industry-academia partnerships, promoting the localization of high-end ophthalmic treatment equipment and supporting the self-control and technological upgrades of the related industry chain [12]. - Looking ahead, the team plans to deepen collaboration with the industry to promote more original and leading technologies for clinical application, contributing to the high-quality development of eye health in China and supporting the "Healthy China" strategic goal [14].

Core Insights - The biopharmaceutical industry in China is a strategic emerging industry, crucial for public health, technological innovation, and enhancing national pharmaceutical autonomy. The market size is projected to grow from CNY 4,210 billion in 2022 to CNY 8,000 billion by 2028, with an annual growth rate stabilizing between 10%-12% [1][2][23]. Industry Overview - In 2020, the biopharmaceutical market in China was valued at CNY 3,457 billion, increasing to CNY 4,100 billion in 2021, representing an 18.6% year-on-year growth. However, growth slowed to 2.68% in 2022, with a slight increase to CNY 4,210 billion [1][2]. - The industry is segmented into upstream (raw materials and medical devices), midstream (drug synthesis and production), and downstream (drug distribution). Biopharmaceuticals and chemical drugs have higher profit margins, with biopharmaceutical companies reporting gross margins of 80%-86% [2][4]. Xiamen Biopharmaceutical Industry - Xiamen is a key hub for biopharmaceutical industry development, recognized as a national strategic emerging industry cluster. The local government has implemented various supportive policies since 2016, focusing on innovation and industrialization [6][9]. - The industrial output value of Xiamen's biopharmaceutical sector reached CNY 1,045.87 billion in 2022, with a slight decline to CNY 847 billion in 2023, and is projected to stabilize around CNY 840 billion in 2024 [17][18]. Policy Environment - Xiamen's government has introduced multiple measures to support the biopharmaceutical industry, including financial incentives for R&D and commercialization, with significant rewards for new drug development and medical device innovation [9][26]. - The city aims to establish a CNY 100 billion venture capital fund and enhance the entire process from R&D to clinical application by 2025 [23][26]. Future Outlook - By 2025, Xiamen plans to significantly increase the number of registered biopharmaceutical companies, with projections indicating over 2,200 registered firms, marking a notable rise from previous years [18]. - The city aims to develop a CNY 700 billion biopharmaceutical industry chain, supported by specialized parks and a focus on various sub-sectors, including biopharmaceuticals and medical devices [23][26].

Group 1 - The core point of the article is that Huaxia Eye Hospital announced the resolutions passed during the first meeting of its fourth board of directors, including the election of the chairman and the appointment of the general manager [1] Group 2 - The company approved multiple resolutions, including the election of the chairman of the fourth board of directors and the election of members for the specialized committees [1] - The announcement reflects the company's governance structure and leadership changes, which may impact its strategic direction [1] - The appointment of the general manager is a significant step in the company's operational management [1]

Core Viewpoint - Huaxia Eye Hospital announced the approval of the proposals for the election of the fourth board of directors, including both non-independent and independent director candidates at the first extraordinary shareholders' meeting of 2026 [2] Group 1 - The company held its first extraordinary shareholders' meeting of 2026 on January 14 [2] - The proposals for the election of the fourth board of directors were approved during this meeting [2] - The proposals included nominations for both non-independent and independent director candidates [2]

Core Viewpoint - Huaxia Eye Hospital announced the election of Mr. Zhang Guangbin as the employee representative director of the fourth board of directors during the first employee representative meeting scheduled for January 14, 2026 [2] Group 1 - The company will hold its first employee representative meeting on January 14, 2026 [2] - Mr. Zhang Guangbin has been elected as the employee representative director [2]

上海市锦天城律师事务所 法律意见书 上海市锦天城律师事务所 上海市锦天城律师事务所 关于华厦眼科医院集团股份有限公司 2026 年第一次临时股东会的 法律意见书 地址：上海市浦东新区银城中路 501 号上海中心大厦 9/11/12 层 电话：021-20511000 传真：021-20511999 邮编：200120 关于华厦眼科医院集团股份有限公司 2026 年第一次临时股东会的 为出具本法律意见书，本所及本所律师依据《律师事务所从事证券法律业务 管理办法》和《律师事务所证券法律业务执业规则（试行）》等规定，严格履行 了法定职责，遵循了勤勉尽责和诚实信用原则，对本次股东会所涉及的相关事项 进行了必要的核查和验证，核查了本所认为出具该法律意见书所需的相关文件、 资料，并参加了公司本次股东会的全过程。本所保证本法律意见书所认定的事实 真实、准确、完整，所发表的结论性意见合法、准确，不存在虚假记载、误导性 陈述或者重大遗漏，并愿意承担相应法律责任。 本所同意将本法律意见书与本次股东会的决议一并进行公告，并依法对发表 的法律意见承担相应法律责任。 鉴此，本所律师根据上述法律、法规、规章及规范性文件的要求，按照律师 ...

华厦眼科医院集团股份有限公司 关于董事会完成换届选举及 聘任高级管理人员、证券事务代表的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 证券代码：301267 证券简称：华厦眼科 公告编号：2026-004 华厦眼科医院集团股份有限公司（以下简称"公司"）于 2026 年 1 月 14 日召开 2026 年第一次临时股东会、2026 年第一次职工代表大会及第四届董事 会第一次会议，完成了公司董事会的换届选举及高级管理人员和证券事务代表 的换届聘任。现将有关情况公告如下： 一、公司第四届董事会组成情况 公司第四届董事会由7名董事组成，其中非独立董事3名，独立董事3名，职 工代表董事1名，任期自公司2026年第一次临时股东会选举通过之日起三年。具 体组成情况如下： 1、非独立董事： （1）非职工代表董事：苏庆灿、陈凤国、李晓峰； （2）职工代表董事：张广斌； 2、独立董事：傅元略（会计专业人士）、王志强（会计专业人士）、郑文 礼。 其中，苏庆灿先生为公司第四届董事会董事长。 公司第四届董事会中兼任公司高级管理人员以及由职工代表担任的董事人 数未超过公司董事总 ...

证券代码：301267 证券简称：华厦眼科 公告编号：2026-001 华厦眼科医院集团股份有限公司 2026年第一次临时股东会决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 特别提示： 1、本次股东会不存在否决议案的情形。 2、本次股东会不涉及变更前次股东会已通过的决议。 一、会议召开和出席情况 （一）会议召开情况 1、股东会届次：2026 年第一次临时股东会。 2、会议召开时间 （1）现场会议时间：2026 年 1 月 14 日下午 14:30； （2）网络投票时间：2026 年 1 月 14 日； 通过深圳证券交易所交易系统进行网络投票的具体时间为：2026 年 1 月 14 日 9:15-9:25、9:30-11:30 和 13:00-15:00； 通过深圳证券交易所互联网投票系统投票的具体时间为：2026 年 1 月 14 日 9:15 至 15:00 的任意时间。 3、会议地点：厦门市湖里区五通西路 999 号 17 楼大会议室。 4、会议召开方式：本次股东会采用现场投票与网络投票相结合的方式召开。 5、会议召集人：公司董事会 6、会议主 ...

根据《中华人民共和国公司法》《深圳证券交易所创业板股票上市规则》《深 圳证券交易所上市公司自律监管指引第 2 号——创业板上市公司规范运作》等法 律法规、规范性文件及《公司章程》的相关规定，华厦眼科医院集团股份有限公 司（以下简称"公司"）董事会设置职工代表董事 1 名。 公司于 2026 年 1 月 14 日召开 2026 年第一次职工代表大会，经全体与会职 工代表审议，会议选举张广斌先生担任公司第四届董事会职工代表董事（简历详 见附件）。 证券代码：301267 证券简称：华厦眼科 公告编号：2026-002 华厦眼科医院集团股份有限公司 关于选举第四届董事会职工代表董事的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 2026 年 1 月 14 日 附件： 张广斌简历 张广斌，男，1968 年出生，中国国籍，无境外永久居留权，博士学历，主 任医师，教授，硕士研究生导师。现任公司董事、厦门眼科中心副院长、白内障 专科学科带头人。同时，张广斌先生现任中华医学会眼科学分会白内障与屈光手 术学组委员；中国医师协会眼科医师分会第六届委员会委员及白内障学组委员 ...